肝细胞癌超声造影研究热点与进展

侯雯菲; 汤珈嘉; 杨萌

doi:10.12449/JCH260707

肝细胞癌超声造影研究热点与进展

DOI: 10.12449/JCH260707

中国医学科学院北京协和医院超声医学科，北京 100730

基金项目:

国家自然科学基金青年科学基金项目 (62325112);

国家自然科学基金联合基金项目 (U22A2023);

中国医学科学院医学与健康科技创新工程项目 (2025-I2M-XHJC-003);

中央级公益性科研院所基本科研业务费项目 (2024-RC320-02)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：侯雯菲负责构思文章内容，数据分析，撰写文章；汤珈嘉参与数据分析及撰写文章；杨萌负责全面指导文章撰写，终审文章及最终定稿。

详细信息

通信作者:
杨萌， yangmeng_pumch@126.com （ORCID： 0000-0002-4339-0411）

计量
- 文章访问数: 3
- HTML全文浏览量: 0
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2026-05-20
- 录用日期: 2026-07-13
- 出版日期: 2026-07-25

Research hotspots and advances in contrast-enhanced ultrasound for hepatocellular carcinoma

Department of Ultrasound Medicine，Peking Union Medical College Hospital，Chinese Academy of Medical Sciences，Beijing 100730，China

Research funding:

National Natural Science Foundation of China (62325112);

National Natural Science Foundation of China (U22A2023);

CAMS Innovation Fund for Medical Sciences (2025-I2M-XHJC-003);

Fundamental Research Funds for the Central Public-interest Scientific Institution of Chinese Academy of Medical Sciences (2024-RC320-02)

More Information

Corresponding author: Yang Meng， yangmeng_pumch@126.com （ORCID： 0000-0002-4339-0411）

摘要

摘要: 肝细胞癌是最常见的原发性肝癌类型，整体预后较差。超声造影在肝细胞癌的诊断、疗效评估及预后判断等方面具有重要价值。本文系统梳理了超声造影在肝细胞癌领域的文献特征、研究热点与前沿进展。该领域年发文量总体呈稳步增长趋势，中国在发文总量上居全球首位。高被引文献高度集中于临床指南与标准化规范。关键词分析结果显示，该领域研究热点主要包括肝细胞癌诊断与标准化评估、鉴别诊断、局部治疗后疗效评价及预后预测。同时，微血管侵犯、人工智能及超分辨超声等可能成为当前领域的前沿方向。其中，人工智能可应用于肝细胞癌辅助诊断、肿瘤生物学特征评估及预后预测，而超分辨超声可突破衍射极限，实现肝脏微血管精确成像。当前，肝细胞癌超声造影已有坚实的研究基础，具有较强的临床实践导向。未来基于超声造影的人工智能模型及超分辨超声等新技术有望进一步推动肝细胞癌精准诊疗的发展。
- 癌，肝细胞 /
- 超声造影 /
- 文献计量学 /
- 人工智能 /
- 超分辨超声
Abstract: Hepatocellular carcinoma （HCC） is the most common type of primary liver cancer and has a poor overall prognosis. Contrast-enhanced ultrasound （CEUS） plays a crucial role in the diagnosis， treatment response evaluation， and prognostic evaluation of HCC. This article systematically reviews the literature characteristics， research hotspots， and frontier advances of CEUS in the field of HCC. There has been a gradual increase in annual publication volume in this field， with China ranking first globally in the total number of publications. Highly cited articles mainly focus on clinical guidelines and standardized protocols. Keyword analysis shows that the main research hotspots in this field include the diagnosis and standardized assessment of HCC， differential diagnosis， treatment response evaluation after local therapy， and prognostic prediction. Meanwhile， microvascular invasion， artificial intelligence （AI）， and super-resolution ultrasound （SRUS） may be emerging as cutting-edge frontiers in this field. Specifically， AI can be used for the auxiliary diagnosis of HCC， the evaluation of tumor biological characteristics， and prognostic prediction， and SRUS can overcome the acoustic diffraction limit to achieve precise microvascular imaging of the liver. Currently， a solid foundation has been established for the research on CEUS in HCC， showing a strong orientation toward clinical practice. In the future， emerging technologies such as CEUS-based AI models and SRUS are expected to further promote the development of precise diagnosis and treatment for HCC.
- Carcinoma， Hepatocellular /
- Contrast Enhanced Ultrasound /
- Bibliometrics /
- Artificial Intelligence /
- Super Resolution Ultrasound

HTML全文

图附录A~J见二维码

下载: 全尺寸图片幻灯片

表 1 超声造影相关技术方向及代表性关键词

Table 1. CEUS-related technical directions and representative keywords

技术方向	相关关键词
造影剂	contrast agent、ultrasound contrast agents、Sonazoid、SonoVue、nanobubbles
多模态评估	Doppler、elastography、multiparametric ultrasound、fusion imaging
人工智能算法应用	artificial intelligence、deep learning、machine learning、radiomics、segmentation、prediction model
超分辨超声	microvascular imaging、localization microscopy、ultrasound localization microscopy、super-resolution ultrasound、tracking

下载: 导出CSV

参考文献(52)

[1]	Chan Y T, Zhang C, Wu J Y, et al. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma[J]. Mol Cancer, 2024, 23( 1): 189. DOI: 10.1186/s12943-024-02101-z.
[2]	Moris D, Martinino A, Schiltz S, et al. Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians[J]. CA Cancer J Clin, 2025, 75( 6): 498- 527. DOI: 10.3322/caac.70018.
[3]	Sangro B, Argemi J, Ronot M, et al. EASL clinical practice guidelines on the management of hepatocellular carcinoma[J]. J Hepatol, 2025, 82( 2): 315- 374. DOI: 10.1016/j.jhep.2024.08.028.
[4]	Singal A G, Llovet J M, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma[J]. Hepatology, 2023, 78( 6): 1922- 1965. DOI: 10.1097/HEP.0000000000000466.
[5]	Dietrich C F, Nolsøe C P, Barr R G, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound(CEUS) in the liver- update 2020- WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS[J]. Ultraschall Med, 2020, 41( 5): 562- 585. DOI: 10.1055/a-1177-0530.
[6]	National Health Commission of the People’s Republic of China. Guideline for diagnosis and treatment of primary liver cancer(2026 edition)[J]. J Clin Hepatol, 2026, 42( 4): 794- 827. DOI: 10.12449/JCH260409. 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2026年版)[J]. 临床肝胆病杂志, 2026, 42( 4): 794- 827. DOI: 10.12449/JCH260409.
[7]	Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7: 7. DOI: 10.1038/s41572-021-00245-6.
[8]	Galle P R, Forner A, Llovet J M, et al. EASL clinical practice guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69( 1): 182- 236. DOI: 10.1016/j.jhep.2018.03.019.
[9]	Piscaglia F, Wilson S, Lyshchik A, et al. American College of Radiology Contrast Enhanced Ultrasound Liver Imaging Reporting and Data System(CEUS LI-RADS) for the diagnosis of Hepatocellular Carcinoma: A pictorial essay[J]. Ultraschall Med, 2017, 38( 3): 320- 324. DOI: 10.1055/s-0042-124661.
[10]	Aubé C, Oberti F, Lonjon J, et al. EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice[J]. Liver Int, 2017, 37( 10): 1515- 1525. DOI: 10.1111/liv.13429.
[11]	Lyshchik A, Fetzer D T, Kono Y, et al. Liver imaging reporting and data system contrast-enhanced US nonradiation treatment response assessment version 2024[J]. Radiology, 2024, 311( 2): e232369. DOI: 10.1148/radiol.232369.
[12]	van der Pol C B, McInnes M D F, Salameh J P, et al. CT/MRI and CEUS LI-RADS major features association with hepatocellular carcinoma: Individual patient data meta-analysis[J]. Radiology, 2023, 307( 1): e239005. DOI: 10.1148/radiol.239005.
[13]	van der Pol C B, Lim C S, Sirlin C B, et al. Accuracy of the liver imaging reporting and data system in computed tomography and magnetic resonance image analysis of hepatocellular carcinoma or overall malignancy-a systematic review[J]. Gastroenterology, 2019, 156( 4): 976- 986. DOI: 10.1053/j.gastro.2018.11.020.
[14]	Zhou Y, Qin Z Y, Ding J M, et al. Risk stratification and distribution of hepatocellular carcinomas in CEUS and CT/MRI LI-RADS: A meta-analysis[J]. Front Oncol, 2022, 12: 873913. DOI: 10.3389/fonc.2022.873913.
[15]	Yang D H, Chen X J, Huang L J, et al. Correlation between CEUS LI-RADS categorization of HCC < 20 mm and clinic-pathological features[J]. Insights Imaging, 2024, 15( 1): 110. DOI: 10.1186/s13244-024-01688-7.
[16]	Terzi E, Iavarone M, Pompili M, et al. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1, 006 nodules[J]. J Hepatol, 2018, 68( 3): 485- 492. DOI: 10.1016/j.jhep.2017.11.007.
[17]	Vilana R, Forner A, Bianchi L, et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound[J]. Hepatology, 2010, 51( 6): 2020- 2029. DOI: 10.1002/hep.23600.
[18]	Galassi M, Iavarone M, Rossi S, et al. Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound[J]. Liver Int, 2013, 33( 5): 771- 779. DOI: 10.1111/liv.12124.
[19]	Li F, Li Q, Liu Y B, et al. Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: The evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017[J]. Eur Radiol, 2020, 30( 1): 461- 470. DOI: 10.1007/s00330-019-06317-2.
[20]	Yang J, Zhang Y H, Li J W, et al. Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. World J Gastroenterol, 2020, 26( 46): 7325- 7337. DOI: 10.3748/wjg.v26.i46.7325.
[21]	Wen R, Lin P, Wu Y Q, et al. Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma[J]. Eur J Radiol, 2022, 154: 110415. DOI: 10.1016/j.ejrad.2022.110415.
[22]	Hai Y, Savsani E, Chong W, et al. Meta-analysis and systematic review of contrast-enhanced ultrasound in evaluating the treatment response after locoregional therapy of hepatocellular carcinoma[J]. Abdom Radiol(NY), 2021, 46( 11): 5162- 5179. DOI: 10.1007/s00261-021-03248-9.
[23]	Nam K, Stanczak M, Lyshchik A, et al. Evaluation of hepatocellular carcinoma transarterial chemoembolization using quantitative analysis of 2D and 3D real-time contrast enhanced ultrasound[J]. Biomed Phys Eng Express, 2018, 4( 3): 035039. DOI: 10.1088/2057-1976/aabb14.
[24]	Sparchez Z, Mocan T, Radu P, et al. Contrast enhanced ultrasonography in assessing the treatment response to transarterial chemoembolization in patients with hepatocellular carcinoma[J]. Med Ultrason, 2016, 18( 1): 96- 102. DOI: 10.11152/mu.2013.2066.181.scz.
[25]	Faccia M, Garcovich M, Ainora M E, et al. Contrast-enhanced ultrasound for monitoring treatment response in different stages of hepatocellular carcinoma[J]. Cancers, 2022, 14( 3): 481. DOI: 10.3390/cancers14030481.
[26]	Yan S Y, Zhang Y, Sun C, et al. Comparison of real-time contrast-enhanced ultrasonography and standard ultrasonography in liver cancer microwave ablation[J]. Exp Ther Med, 2016, 12( 3): 1345- 1348. DOI: 10.3892/etm.2016.3448.
[27]	Eisenbrey J R, Gabriel H, Savsani E, et al. Contrast-enhanced ultrasound(CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies[J]. Abdom Radiol, 2021, 46( 8): 3579- 3595. DOI: 10.1007/s00261-021-03059-y.
[28]	Kuon Yeng Escalante C M, Siu Xiao T, Nagaraj R U, et al. Evaluation of the contrast-enhanced ultrasound nonradiation treatment response assessment LI-RADS v2024 using data from a multi-center transarterial chemoembolization study[J]. Acad Radiol, 2024, 31( 12): 5078- 5086. DOI: 10.1016/j.acra.2024.06.005.
[29]	Cao J Y, Dong Y, Xu X L, et al. LI-RADS CEUS nonradiation TRA version 2024: Application on HCC patients treated with ablation treatment[J]. Ultrasound Med Biol, 2025, 51( 8): 1308- 1315. DOI: 10.1016/j.ultrasmedbio.2025.04.018.
[30]	Tu H B, Feng S Y, Chen L H, et al. Contrast enhanced ultrasound combined with serology predicts hepatocellular carcinoma recurrence: A retrospective observation cohort study[J]. Front Oncol, 2023, 13: 1154064. DOI: 10.3389/fonc.2023.1154064.
[31]	Cao K P, Wu L X, Wang X Y, et al. Risk factors for early recurrence after radical resection of hepatocellular carcinoma based on preoperative contrast-enhanced ultrasound and clinical features[J]. Technol Cancer Res Treat, 2024, 23: 15330338241281327. DOI: 10.1177/15330338241281327.
[32]	Gu D Y, Zhang Y, Hu J X, et al. The value of contrast-enhanced ultrasound quantitative parameters in the prognosis prediction of hepatocellular carcinoma after thermal ablation: A retrospective cohort study[J]. J Gastrointest Oncol, 2022, 13( 5): 2522- 2531. DOI: 10.21037/jgo-22-919.
[33]	Ma Q P, He X L, Li K, et al. Dynamic contrast-enhanced ultrasound radiomics for hepatocellular carcinoma recurrence prediction after thermal ablation[J]. Mol Imaging Biol, 2021, 23( 4): 572- 585. DOI: 10.1007/s11307-021-01578-0.
[34]	Huang Z, Shu Z, Zhu R H, et al. Deep learning-based radiomics based on contrast-enhanced ultrasound predicts early recurrence and survival outcome in hepatocellular carcinoma[J]. World J Gastrointest Oncol, 2022, 14( 12): 2380- 2392. DOI: 10.4251/wjgo.v14.i12.2380.
[35]	Liu F, Liu D, Wang K, et al. Deep learning radiomics based on contrast-enhanced ultrasound might optimize curative treatments for very-early or early-stage hepatocellular carcinoma patients[J]. Liver Cancer, 2020, 9( 4): 397- 413. DOI: 10.1159/000505694.
[36]	Ding W Z, Meng Y Q, Ma J, et al. Contrast-enhanced ultrasound-based AI model for multi-classification of focal liver lesions[J]. J Hepatol, 2025, 83( 2): 426- 439. DOI: 10.1016/j.jhep.2025.01.011.
[37]	Xiao M Q, Deng Y S, Zheng W, et al. Machine learning model based on dynamic contrast-enhanced ultrasound assisting LI-RADS diagnosis of HCC: A multicenter diagnostic study[J]. Heliyon, 2024, 10( 20): e38850. DOI: 10.1016/j.heliyon.2024.e38850.
[38]	Su L Y, Xu M, Chen Y L, et al. Ultrasomics in liver cancer: Developing a radiomics model for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma using contrast-enhanced ultrasound[J]. World J Radiol, 2024, 16( 7): 247- 255. DOI: 10.4329/wjr.v16.i7.247.
[39]	Wang Y J, Weng W X, Liang R M, et al. Predicting T cell-inflamed gene expression profile in hepatocellular carcinoma based on dynamic contrast-enhanced ultrasound radiomics[J]. J Hepatocell Carcinoma, 2023, 10: 2291- 2303. DOI: 10.2147/JHC.S437415.
[40]	Xu W X, Zhang H Y, Zhang R, et al. Deep learning model based on contrast-enhanced ultrasound for predicting vessels encapsulating tumor clusters in hepatocellular carcinoma[J]. Eur Radiol, 2025, 35( 2): 989- 1000. DOI: 10.1007/s00330-024-10985-0.
[41]	Wang Y Q, Xie W T, Li C X, et al. Automated microvascular invasion prediction of hepatocellular carcinoma via deep relation reasoning from dynamic contrast-enhanced ultrasound[J]. Comput Med Imaging Graph, 2025, 124: 102606. DOI: 10.1016/j.compmedimag.2025.102606.
[42]	Chen Z X, Liu S Y, Tong X M. Preoperative prediction of microvascular invasion: Is invasive biopsy of HCC necessary?[J]. J Hepatol, 2022, 77( 3): 892- 893. DOI: 10.1016/j.jhep.2022.04.016.
[43]	Chen K K, Zhang S K, Huang T J, et al. CEUS-based microvascular invasion predictor in HCC: Improving prognostic stratification following thermal ablation[J]. Liver Int, 2026, 46( 6): e70661. DOI: 10.1111/liv.70661.
[44]	Lu D, Wang L F, Han H, et al. Prediction of microvascular invasion in hepatocellular carcinoma with conventional ultrasound, Sonazoid-enhanced ultrasound, and biochemical indicator: A multicenter study[J]. Insights Imaging, 2024, 15( 1): 261. DOI: 10.1186/s13244-024-01743-3.
[45]	Sun Y T, Yang H, Li S R, et al. An accurate model for microvascular invasion prediction in solitary hepatocellular carcinoma ≤5 cm based on CEUS and EOB-MRI: A retrospective study with external validation[J]. Acad Radiol, 2025, 32( 9): 5173- 5186. DOI: 10.1016/j.acra.2025.04.021.
[46]	Cerrito L, Ainora M E, Cuccia G, et al. Dynamic contrast-enhanced ultrasound in the prediction of advanced hepatocellular carcinoma response to systemic and locoregional therapies[J]. Cancers, 2024, 16( 3): 551. DOI: 10.3390/cancers16030551.
[47]	Errico C, Pierre J, Pezet S, et al. Ultrafast ultrasound localization microscopy for deep super-resolution vascular imaging[J]. Nature, 2015, 527( 7579): 499- 502. DOI: 10.1038/nature16066.
[48]	Dencks S, Schmitz G. Ultrasound localization microscopy[J]. Z Für Med Phys, 2023, 33( 3): 292- 308. DOI: 10.1016/j.zemedi.2023.02.004.
[49]	Wang F Q, Yu J T, Lu X Q, et al. Relationship between contrast-enhanced ultrasound combined with ultrasound resolution microscopy imaging and histological features of hepatocellular carcinoma[J]. Abdom Radiol, 2025, 50( 8): 3530- 3542. DOI: 10.1007/s00261-025-04825-y.
[50]	Zeng Q Q, An S Z, Chen C N, et al. Focal liver lesions: Multiparametric microvasculature characterization via super-resolution ultrasound imaging[J]. Eur Radiol Exp, 2024, 8( 1): 138. DOI: 10.1186/s41747-024-00540-3.
[51]	Brown K G, Li J J, Margolis R, et al. Assessment of transarterial chemoembolization using super-resolution ultrasound imaging and a rat model of hepatocellular carcinoma[J]. Ultrasound Med Biol, 2023, 49( 5): 1318- 1326. DOI: 10.1016/j.ultrasmedbio.2023.01.021.
[52]	Subudhi S, Lee S, Jain R K. Targeting angiogenesis: Lessons from 25 years of normalizing tumor vasculature[J]. Cell, 2026, 189( 8): 2379- 2415. DOI: 10.1016/j.cell.2026.03.016.